DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Onyx Biotec Limited (ONYX) share price today?

Onyx Biotec Limited (ONYX) is trading at ₹37.25 on the NSE, up 0.54% on the day. Source: DocStoX.

What is the PE ratio of Onyx Biotec Limited?

Onyx Biotec Limited has a price-to-earnings (PE) ratio of -322.9 in the Healthcare sector.

What is the market capitalisation of Onyx Biotec Limited?

Onyx Biotec Limited has a market capitalisation of approximately ₹68 crore.

Is Onyx Biotec Limited a profitable company?

Onyx Biotec Limited generates a return on equity of -0.4% with a net profit margin of -0.3%. That is a modest return on shareholder capital.

What is the 52-week high and low of ONYX?

Onyx Biotec Limited (ONYX) has traded between ₹24.2 and ₹49.65 over the past 52 weeks, against a current price of ₹37.25.

Onyx Biotec Limited

₹37.25▲ +0.20 (+0.54%)

ONYX·NSE·Healthcare

Market Cap

67.54 Cr

PE Ratio

-322.90

Volume

2,000

Day High - Low

37.25 - 37.25

52W High-Low

49.65 - 24.20

₹37.25▲ +0.20 (+0.54%)

Market Cap67.54 Cr

PE Ratio-322.90

Volume2,000

Day High - Low37.25 - 37.25

52W High-Low49.65 - 24.20

Onyx Biotec Limited (ONYX): company summary

The company's revenue grew 12.1% annually, reaching ₹69 crore, but net profit swung to a loss of ₹0 crore from a profit of ₹5 crore.

Onyx Biotec Limited (ONYX) is a micro-cap Healthcare company valued at ₹68 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Onyx Biotec Limited last traded at ₹37.25, modestly up 0.54% on the day.
Recent developments: On 2026-03-31, the company reported a net loss of ₹0 crore for the latest financial year, reversing a prior year profit of ₹5 crore. The latest quarter ended on the same date with a net profit of ₹1 crore, down from ₹2 crore in the prior year's quarter.
Financial performance: The company's revenue grew 12.1% annually, reaching ₹69 crore, but net profit swung to a loss of ₹0 crore from a profit of ₹5 crore. The latest quarter saw revenue rise 9.7% year-on-year to ₹35 crore, but net profit fell 65.0% to ₹1 crore, indicating pressure on profitability.
Valuation multiples: A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at 1.27 times book value.
Things to watch: The company reported a net loss of ₹0 crore in the latest financial year, reversing a prior year profit. Net profit margin fell to -0.3% from 8.0% a year earlier, and return on equity is negative at -0.4%. The stock is 24.4% below its 52-week high.
Where it stands: Onyx Biotec Limited ended its latest financial year with a net loss of ₹0 crore, reversing a prior year profit. The stock is 24.4% below its 52-week high, and net profit margin has dropped to -0.3%. The latest quarter's net profit of ₹1 crore marks a significant decline from ₹2 crore a year earlier.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

5.0/10

Weak

Fair Value

ROE

-0.39%

Weak

P/E

-322.90x

Loss-making

Debt / Equity

0.27

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

52W₹24.20

₹49.65

DocStoX take

Supported by growth (7.5) and risk (6.6), but held back by quality (1.5). Growth looks strong at 7.5, but that is offset by quality at 1.5. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

5.0

/10

Weak

Quality

Weak

ROE -0.4%

Valuation

Fair

P/B 1.3× on assets (no earnings to value)

Growth

Strong

Revenue +20.7% 3Y CAGR

Risk

Moderate

D/E 0.27

Momentum

Firm

51% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹37

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹68 Cr

52W High / Low

₹50 / ₹24

Dividend Yield

0.00%

Promoter Holding

65.10%

EPS (TTM)

₹-0.12

Book Value

₹30.56

Key highlights

Revenue compounding 21% a year
Loss-making — no meaningful P/E
Quality is weak (1.5/10)

1 Positive3 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Onyx Biotec Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Onyx Biotec Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Zydus Lifesciences Limited Laurus Labs Limited Cipla Limited Dr. Reddy's Laboratories Limited Aurobindo Pharma Limited Mankind Pharma Limited Lupin Limited Manipal Health Enterprises Limited

Compare Onyx Biotec Limited with peers

Onyx Biotec Limited vs Sun Pharmaceutical Industries Limited Onyx Biotec Limited vs Divi's Laboratories Limited Onyx Biotec Limited vs Torrent Pharmaceuticals Limited Onyx Biotec Limited vs Apollo Hospitals Enterprise Limited Onyx Biotec Limited vs Zydus Lifesciences Limited Onyx Biotec Limited vs Laurus Labs Limited

Related tools & concepts

Value Onyx Biotec Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

ONYX newsLatest coverage & filings Open screenerFilter the whole market